Financials in CAD. Standardized financial statements.
A compact view of how Pharmala Biotech Holdings Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue? | $605,498 | $1.04M | $532,003 | $78,070 | $0 |
| Revenue Growth? | -41.5% | +94.6% | +581.4% | 0.0% | 0.0% |
| Cost of Revenue? | $1.45M | $147,856 | $77,904 | $2,288 | $303 |
| Gross Profit? | -$845,170 | $887,441 | $454,099 | $75,782 | -$303 |
| Gross Margin? | -139.6% | +85.7% | +85.4% | +97.1% | 0.0% |
| Operating Expenses? | $1.31M | $1.53M | $1.22M | $1.06M | $2.51M |
| Operating Income? | -$2.15M | -$643,566 | -$762,950 | -$985,583 | -$2.51M |
| EBITDA? | -$2.07M | -$573,357 | -$710,185 | -$973,448 | -$2.51M |
| Income Before Tax | -$2.18M | -$823,596 | -$779,813 | -$985,583 | -$2.51M |
| Income Tax Expense | $0 | -$157,430 | $0 | -$3 | $0 |
| Net Income? | -$2.18M | -$823,596 | -$779,813 | -$985,583 | -$2.51M |
| EPS? | $-0.02 | $-0.01 | $-0.01 | $-0.01 | $-0.03 |
| Diluted EPS? | $-0.02 | $-0.01 | $-0.01 | $-0.01 | $-0.03 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality